Diagnostic checking in regression relationships
Although achieving surrogate histopathological endpoints is considered by regulatory agencies to likely translate to improved prognosis, robust evidence is needed to understand if GLP1 agonists reduce the risk of long-term clinical outcomes, such as liver decompensation or HCC, Axel Wester, MD, PhD, assistant professor of medicine at Karolinska Institute, and colleagues wrote
Those blue-green cellular factories, labeled L-cells, are already poised to manufacture a powerful biological signal called GLP-1
M., Boutron, I., Hoffmann, T
DOI.org (Crossref) , International Archives of Allergy and Applied Immunology , vol